Home › Kanser sa Ovary › Louisiana
Pag-aaral pangklinika para sa Kanser sa Ovary sa Louisiana
19 pag-aaral para sa Kanser sa Ovary ang naghahanap ng mga kalahok sa mga site sa Louisiana.
Mga Lungsod sa Louisiana
Opisyal na teksto ng pag-aaral (English)
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Louisiana State University HSC - NO Cancer Center, New Orleans
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Okt 5, 2026 · NCT06915025Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- University Medical Center New Orleans, New Orleans
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT07001748Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Ochsner Medical Center Jefferson, New Orleans
Nagre-recruitPhase 2
Lahat ng edad · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05564377Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Ochsner Clinic Foundation, New Orleans
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Kababaihan · Na-update Set 29, 2026 · NCT05051722A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Women'S Cancer Care /ID# 276469, Covington
- University Medical Center New Orleans /ID# 274755, New Orleans
- Trials 365 /ID# 274310, Shreveport
Nagre-recruitPhase 2
Edad 18 pataas · Kababaihan · Na-update Set 29, 2026 · NCT06890338A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Ochsner Clinic Foundation, New Orleans
- Trials 365, Shreveport
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07213804A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Our Lady of the Lake Physician Group - Medical Oncology /ID# 277440, Baton Rouge
Nagre-recruitPhase 2
Edad 18 pataas · Kababaihan · Na-update Set 22, 2026 · NCT07059845A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Women's Cancer Care ( Site 0018), Covington
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Set 17, 2026 · NCT07318558Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Women'S Cancer Care, Covington
- Trials365, Llc, Shreveport
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Set 15, 2026 · NCT07214779A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Trials365, Llc, Shreveport
Nagre-recruitPhase 2
Edad 18 hanggang 99 · Kababaihan · Na-update Set 15, 2026 · NCT07023627ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Tulane Cancer Center, New Orleans
- Christus Highland/ Boniol, Shreveport
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT05059444A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Women's Cancer Care ( Site 0067), Covington
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Set 3, 2026 · NCT06824467A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- West Jefferson Medical Center, Marrero
- Louisiana State University Health Science Center, New Orleans
- University Medical Center New Orleans, New Orleans
- at 1 pa
Nagre-recruit
Edad 35 hanggang 50 · Kababaihan · Na-update Ago 7, 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- LSU Health Baton Rouge-North Clinic, Baton Rouge
- Our Lady of the Lake Physician Group, Baton Rouge
- Our Lady of The Lake, Baton Rouge
- at 8 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT06580314A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Our Lady of the Lake, Baton Rouge
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 30, 2026 · NCT04657068First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Louisiana State University Health Sciences Center, New Orleans
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 7, 2026 · NCT05768139Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Trials365 LLC, Shreveport
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Hul 2, 2026 · NCT06819007Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
- LSU Health New Orleans, New Orleans
- University Medical Center New Orleans, New Orleans
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Abr 16, 2026 · NCT05659381SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, New Orleans
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.